Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 76,200 shares, a growth of 150.7% from the November 30th total of 30,400 shares. Based on an average daily volume of 559,900 shares, the days-to-cover ratio is presently 0.1 days.

Astellas Pharma Trading Up 0.7 %

ALPMY stock opened at $9.72 on Friday. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $13.14. The company’s 50-day simple moving average is $10.62 and its 200 day simple moving average is $11.01. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90. The company has a market capitalization of $17.59 billion, a PE ratio of 46.29 and a beta of 0.33.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $3.11 billion during the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. As a group, sell-side analysts anticipate that Astellas Pharma will post 0.61 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.